Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA).

Mol Autism 2018 22;9:12. Epub 2018 Feb 22.

3Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust, Room 3.311, Jean McFarlane Building, Oxford Road, Manchester, M13 9PL UK.

Background: Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/behaviour outcomes have shown mixed results. This trial breaks new ground by studying statin effects for the first time in younger children with NF1 and co-morbid autism and by using multiparametric imaging outcomes.

Methods: A single-site triple-blind RCT of simvastatin vs. placebo was done. Assessment (baseline and 12-week endpoint) included peripheral MAPK assay, awake magnetic resonance imaging spectroscopy (MRS; GABA and glutamate+glutamine (Glx)), arterial spin labelling (ASL), apparent diffusion coefficient (ADC), resting state functional MRI, and autism behavioural outcomes (Aberrant Behaviour Checklist and Clinical Global Impression).

Results: Thirty subjects had a mean age of 8.1 years (SD 1.8). Simvastatin was well tolerated. The amount of imaging data varied by test. Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA ((12) = - 2.12,  = .055), GABA/Glx ratio ((12) = - 2.78,  = .016), and reduced grey nuclei Glx (ANCOVA < 0.05, Mann-Whitney < 0.01); (ii) increased ASL perfusion in ventral diencephalon (Mann-Whitney  < 0.01); and (iii) decreased ADC in cingulate gyrus (Mann-Whitney  < 0.01). Machine-learning classification of imaging outcomes achieved 79% ( < .05) accuracy differentiating groups at endpoint against chance level (64%,  = 0.25) at baseline. Three of 12 (25%) simvastatin cases compared to none in placebo met 'clinical responder' criteria for behavioural outcome.

Conclusions: We show feasibility of peripheral MAPK assay and autism symptom measurement, but the study was not powered to test effectiveness. Multiparametric imaging suggests possible simvastatin effects in brain areas previously associated with NF1 pathophysiology and the social brain network.

Trial Registration: EU Clinical Trial Register (EudraCT) 2012-005742-38 (www.clinicaltrialsregister.eu).

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13229-018-0190-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824534PMC
October 2018
24 Reads

Publication Analysis

Top Keywords

simvastatin treatment
8
diffusion coefficient
4
coefficient adc
4
adc resting
4
apparent diffusion
4
asl apparent
4
glx arterial
4
arterial spin
4
spin labelling
4
labelling asl
4
resting state
4
state functional
4
aberrant behaviour
4
behaviour checklist
4
checklist clinical
4
outcomes aberrant
4
behavioural outcomes
4
functional mri
4
mri autism
4
autism behavioural
4

References

(Supplied by CrossRef)

D Evans et al.
Am J Med Genet 2010

S Hyman et al.
Dev Med Child Neurol 2007

V Mautner et al.
Dev Med Child Neurol 2002

S Garg et al.
Pediatrics 2013

SM Morris et al.
JAMA Psychiatry 2016

AI Molosh et al.
Nat Neurosci 2014

Y Cui et al.
Cell 2008

A Ishii et al.
J Neurosci 2016

DA Mayes et al.
Cell Rep 2013

G Ertan et al.
Neuroradiol J 2014

Similar Publications